The freeze-dried nasal spray influenza attenuated live vaccine of BCHT is the first domestic influenza vaccine to be administered by nasal spray in cooperation with the World Health Organization and included in the WHO Global Influenza Action Plan. It can effectively avoid the harm caused by intramuscular or subcutaneous injection to young children, greatly improving the poor compliance, increasing the vaccination rate of the adaptive population, and the market prospect is promising. Phase I and II clinical trials of freeze-dried nasal spray influenza attenuated live vaccines have obtained special funding support from the 2016 National Key R & D Plan “Key Biosafety Technology R & D”, which applied for and obtained 1 invention patent.

The influenza vaccines currently on the domestic market are all injected intramuscularly or subcutaneously, which leads to poor product compliance, especially in young children, and is a major cause of the current low domestic influenza vaccination rate. The nasal spray attenuated live attenuated vaccine that launched by BCHT will effectively circumvent this deficiency, and it can increase the vaccination rate of the adapted population after launching to the market. At the same time, the vaccine is included in the WHO procurement plan, and BCHT can take this opportunity to actively organize WHO pre-certification, participate in international competition, and increase the global visibility of vaccine industry in China. This product is clearly differentiated from competing products of other domestic manufacturers, which can take higher price and get higher revenue.

At present, the freeze-dried nasal spray influenza attenuated live vaccine has completed clinical trials and applied for production, and is expected to be approved for sale by the end of 2019.